Cardiovascular risk and chronic kidney disease: cardioand nephroprotection strategies


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Разработаны Комитетом экспертов Российского кардиологического общества (РКО), Научного общества нефрологов России (НОНР), Российской ассоциации эндокринологов (РАЭ), Российского медицинского общества по артериальной гипертонии (РМОАГ), Национального общества по изучению атеросклероза (НОА), Российского научного медицинского общества терапевтов (РНМОТ)

Full Text

Restricted Access

About the authors

- -

References

  1. WHO-FIC Network at the annual meeting in Trieste, October 2007. @http://www.who.int/classifications/icd/ICD-10%20Updates%202007.pdf
  2. Matsushita K., van der Velde M., Astor B.C. et al. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis // Lancet. - 2010. - Vol. 375(9731). - P. 2073-2081.
  3. Ronco C., McCullough P., Anker S. et al. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative // Eur Heart J. - 2010. -Vol. 31. - P. 703-711.
  4. Jamerson K., Weber M.A., Bakris G.L. et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients // N Engl J Med. - 2008. - Vol. 359. - P. 2417-2428.
  5. Bakris G.L., Serafidis P.A., Weir M.R. et al. ACCOMPLISH Trial Investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of randomized controlled trial // Lancet. - 2010. - Vol. 375. -P. 1173-1181.
  6. Patel A., MacMahon S., Chalmers J. et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial // Lancet. - 2007. - Vol. 370. - P. 829-840.
  7. de Galan B.E., Perkovic V., Ninomiya T. et al. ADVANCE Collaborative Group. Lowering blood pressure reduces renal events in type 2 diabetes // J Am Soc Nephrol. - 2009. - Vol. 20. - P. 883-892.
  8. Parving H.H., Brenner B.M., McMurray J.J.V. et al. Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes // N Engl J Med. - 2012. - Vol. 367. - P. 2204-2213.
  9. Bart B.A., Goldsmith S.R., Lee K.L. et al. Ultrafiltration in decompensated heartfailure with cardiorenal syndrome // N Engl J Med. - 2012. - Vol. 367(24). - P. 2296-2304.
  10. Mann J.F.E., Schmieder R.E., McQueen M. et al. Renal outcomes with telmisartan, ramipril, or both in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind controlled trial // Lancet. - 2008. - Vol. 372. - P. 547-553.
  11. Haller H., Ito S., Izzo J.L. Jr. et al. ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes // N Engl J Med. - 2011. -Vol. 364. - P. 907-917
  12. Baigent C., Landray M.J., Reith C. et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial // Lancet. - 2011. - Vol. 377(9784). - P. 2181-2192.
  13. Рабочая группа членов правления Научного общества нефрологов России. Национальные рекомендации. Хроническая болезнь почек: основные положения, определение, диагностика, скрининг, подходы к профилактике и лечению. -2011; @http://journal.nephrolog.ru/ckd/
  14. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease // Kidney Int (Suppl.). - 2013. - Vol. 3. - P. 1-150.
  15. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update // Am J Kidney Dis. - 2012. - Vol. 60(5). - P. 850-886.
  16. Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury // Kidney Int, (Suppl.). - 2012. -Vol. 2. - P. 1-138.
  17. ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // Eur Heart J. - 2013. -Vol. 34. - P. 2159-2219.
  18. Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная терапия и профилактика. - 2011. - 10 (6). Приложение 2. @http://scardio.ru/rekomendacii/rekomendacii_rko/
  19. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) // Eur Heart J. - 2012. - Vol. 33. - P. 1635-1701.
  20. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. V пересмотр. - М. - 2012. @ http://cardioline.ru/uploads/Full%20Guidelines.pdf
  21. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) // Eur Heart J. - 2011. - Vol. 32. -P. 1769-1818.
  22. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease // Kidney Int. (Suppl.). - 2013. - Vol. 3. - P. 259-305.
  23. Функциональное состояние почек и прогнозирование сердечно-сосудистого риска. Рекомендации ВНОК и НОНР // Кардиоваскулярная терапия и профилактика. - 2008. - № 7(6), Приложение 3.
  24. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease // Kidney Inter. (Suppl.). - 2012. - № 2.
  25. Клинические практические рекомендации KDIGO по анемии при хронической болезни почек 2012 // Нефрология и диализ. - 2013. - № 15(1). - С. 14-53.
  26. Национальные рекомендации по минеральным и костным нарушениям при хронической болезни почек: Российское диализное общество // Нефрология и диализ. - 2011. - № 13(1). - С. 33-51.
  27. Hemmelgarn B.R., Manns B.J., Tonelli M.; Interdisciplinary Chronic Disease Collaboration. A decade after the KDOQI CKD Guidelines: a perspective from Canada // Am J Kidney Dis. - 2012. - Vol. 60(5). - P. 723-724.
  28. Levey A.S., Stevens L.A., Schmid C.H. et al. A new equation to estimate glomerular filtration rate // Ann Intern Med. - 2009. - Vol. 150. - P. 604- 612.
  29. Middleton R.J., Foley R.N., Hegarty J. et al. The unrecognized prevalence of chronic kidney disease in diabetes // Nephrol Dial Transplant. - 2006. - Vol. 21. - P. 88-92.
  30. Segura J., Garcia-Donair J., Praga M. et al. Chronic kidney disease as a situation of high added risk in hypertensive patients // J Am Soc Nephrol. - 2006. - Vol. 17 (Suppl 2.). - P. 136-140.
  31. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients // Am J Kidney Dis. - 2005. - Vol. 45 (Suppl 3). - P. S1-153.
  32. Go A.S., Chertow G.M., Fan D. et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization // N Engl J Med. - 2004. - Vol. 351. -P. 1296-1305.
  33. Manjunath G., Tighiouart H., Ibrahim H. et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community // J Am Coll Cardiol. - 2003. - Vol. 41(1). - P. 47-55.
  34. Foley R., Murray A., Li S. et al. Chronic kidney disease and the riskfor cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999 // J Am Soc Nephrol. - 2005. - Vol. 16. - P. 489-495.
  35. Clase C.M., Garg A.X., Kiberd B.A. Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III) // J Am Soc Nephrol. - 2002. - Vol. 13(5). - P. 1338-1349.
  36. Anavekar N.S., McMurray J.J., Velazquez E.J. et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction // N Engl J Med. - 2004. - Vol. 351. - P. 1285-1295.
  37. Collins A.J., Vassalotti J.A., Wang C. et al. Who should be targeted for CKD screening? Impact of diabetes, hypertension, and cardiovascular disease // Am J Kidney Dis. -2009. - Vol. 53 (Suppl 3). - P. 71-77.
  38. Herzog C. Kidney disease in cardiology // Nephrol Dial Transplant. - 2008. - Vol. 23(8). - P. 42-46.
  39. McCullough P.A., Li S., Jurkovitz C.T. et al. CKD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004 // Am J Kidney Dis. - 2008. - Vol. 51 (Suppl 2). - P. 38-45.
  40. Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // Eur Heart J. - 2007. - Vol. 28. - P. 1462-1536.
  41. Sarnak M.J., Greene T., Wang X. et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study // Ann Intern Med. - 2005. - Vol. 142. - P. 342-351.
  42. Okin P.M., Devereux R.B., Jern S. et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events // JAMA. - 2004. - Vol. 292. - P. 2343-2349.
  43. Devereux R.B., Wachtell K., Gerdts E. et al. Prognostic significance of left ventricular mass change during treatment of hypertension // JAMA. - 2004. - Vol. 292. -P. 2350-2356.
  44. Okin P.M., Oikarinen L., Viitasalo M. et al. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE) // Circulation. - 2009. - Vol. 119. - P. 1883-1891.
  45. Olsen M.H., Wachtell K., Ibsen H. et al. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study // J Hypertens. - 2006. - Vol. 24. - P. 775-781.
  46. Schmieder R.E., Mann J.F., Schumacher H. et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease // J Am Soc Nephrol. - 2011. - Vol. 22. - P. 1353-1364.
  47. Jardine M.J., Ninomiya T., Perkovic V. et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial // J Am Coll Cardiol. - 2010. - Vol. 56. - P. 956-65.
  48. Wilson P., D’Agostino Rb., Parise H. et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus // Circulation. - 2005. - Vol. 112. -P. 3066-3072.
  49. Кобалава Ж.Д., Моисеев В.С. Концепция кардиоренальных и метаболических соотношений в современной профилактической кардиологии // Кардиоваскулярная терапия и профилактика. - 2008. - № 4. - С. 4-7.
  50. Despres J.-P. Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic risk // Eur Heart J. - 2006. - Vol. 8 (suppl. B). -P. 4-12.
  51. Asia Pacific Cohort Studies Collaboration. The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region // Diabetes Care. - 2003. - Vol. 26. - P. 360-6.
  52. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под ред. И.И. Дедова, М.В. Шестаковой. - 6-й вып. - М. - 2013. @ http://www.endocrincentr.ru/images/material-images/algoritm.pdf
  53. Мухин Н.А., Балкаров И.М., Моисеев В.С. и др. Хронические прогрессирующие нефропатии и образ жизни современного человека // Терапевтический архив. - 2004. - № 9. - С. 5-10.
  54. Кобалава Ж.Д., Котовская Ю.В., Толкачева В.В. и др. Мочевая кислота - ключевой компонент кардиренометаболического континуума // Кардиоваскулярная терапия и профилактика. - 2008. - № 4. - С. 95-100.
  55. Ronco C., McCullough P., Anker S. et al. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative // Eur Heart J. - 2010. -Vol. 31. - P. 703-711.
  56. Adams K.F., Fonarow G.C., Emerman C.L. et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the acute decompensated heart failure national registry (ADHERE) // Am Heart J. - 2005. - Vol. 149. - P. 209-216.
  57. Fonarow G.C., Stough W.G., Abraham W.T. et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry // J Am Coll Cardiol. - 2007. - Vol. 50. -P. 768- 777.
  58. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC // Eur Heart J. - 2012. - Vol. 33. -P. 1787-1847.
  59. Munar M.Y., Singh H. Drug dosing adjustments in patients with chronic kidney disease // Am Fam Phys. - 2007. - Vol. 75(10). - P. 1487-1496.
  60. Roghi A., Savonitto S., Cavallini C. et al. Impact of acute renal failure following percutaneous coronary intervention on long-term mortality // J Cardiovasc Med. - 2008. - Vol. 9. - P. 375-381.
  61. Lassnigg A., Schmid E.R., Hiesmayr M. et al. Impact of minimal increases in serum creatinine on outcome in patients after cardiothoracic surgery: do we have to revise current definitions of acute renal failure? // Crit Care Med. - 2008. - Vol. 36. -P. 1129-1137.
  62. Bagshaw S.M., Lapinsky S., Dial S. et al. Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy // Intensive Care Med. - 2009. - Vol. 35. - P. 871-81.
  63. Latchamsetty R., Fang J., Kline-Rogers E. et al. Prognostic value of transient and sustained increase in in-hospital creatinine on outcomes of patients admitted with acute coronary syndrome // Am J Cardiol. - 2007. - Vol. 99(7). - P. 939-42.
  64. Jose P., Skali H., Anavekar N. et al. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction // J Am Soc Nephrol. -2006. - Vol. 17. - P. 2886-2891.
  65. Gottlieb S.S., Abraham W., Butler J. et al. The prognostic importance of different definitions of worsening renalfunction in congestive heart failure // J Card Fail. - 2002. - Vol. 8. - P. 136-141.
  66. Krumholz H.M., Chen Y.T., Vaccarino V. et al. Correlates and impact on outcomes of worsening renalfunction in patients ≥ 65 years of age with heart failure // Am J Card. -2000. - Vol. 85. - P. 1110-1113.
  67. Cowie M.R., Komajda M., Murray-Thomas T. et al. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH) // Eur Heart J. -2006. - Vol. 27. - P. 1216-1222.
  68. Ronco C., Bellomo R., McCullough P.A. Cardiorenal syndromes in critical care // Contrib Nephrol - Basel: Karger. - 2010 - Vol. 165. - P. 366.
  69. Mielniczuk L.M., Pfeffer M.A., Lewis E.F. et al. Estimated glomerular filtration rate, inflammation, and cardiovascular events after an acute coronary syndrome // Am Heart J. - 2008. - Vol. 155. - P. 725-731.
  70. Gibson C.M., Dumaine R.L., Gelfand E.V. et al: Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome: Observations in 13,307 patients in five TIMI trials // Eur Heart J. - 2004. - Vol. 25(22). - P. 1998-2005.
  71. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC) // Eur Heart J. - 2012. - Vol. 33. - P. 2569-2619.
  72. Szummer K., Lundman P., Jacobson S.H. et al. Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register // J Intern Med. - 2010. - Vol. 268. -P. 40-49.
  73. Fox K.A., Bassand J.P., Mehta S.R. et al. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes // Ann Intern Med. - 2007. - Vol. 147. - P. 304-310.
  74. James S., Budaj A., Aylward P. et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial // Circulation. - 2010. - Vol. 122. - P. 1056-1067.
  75. Alexander K.P., Chen A.Y., Roe M.T. et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes // JAMA. - 2005. - Vol. 294. - P. 3108-3116.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies